spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Phentermine 

 HSMN NewsFeed - 21 Jul 2021
Corium Launches Innovative ADHD Treatment AZSTARYS(TM) (serdexmethylphenidate and dexmethylphenidate) in the U.S. for Patients Age 6 Years and Older
Biopharmaceutical Neurology Product Launch
 HSMN NewsFeed - 20 Sep 2016
KVK Tech Announces FDA-Approval of Lomaira(TM) (phentermine hydrochloride USP) 8 mg tablets, CIV, A Low-Cost, Low-Dose Phentermine That Can Be Used Up To Three Times Daily for Weight Reduction
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jul 2016
VIVUS Announces Favorable Markman Ruling in Qsymia(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 1 May 2013
New Guidelines From American Association of Clinical Endocrinologists Recommend Medical Treatment of Obesity
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 21 Sep 2012
VIVUS Provides Update on the Review of the Qsiva Marketing Authorization Application
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Dec 2011
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
Biopharmaceuticals
 HSMN NewsFeed - 5 Aug 2011
Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 21 Jan 2011
VIVUS Provides Regulatory Update on QNEXA NDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Dec 2010
VIVUS Files European Marketing Authorization Application for QNEXA(R) in the Treatment of Obesity
Biopharmaceuticals
 HSMN NewsFeed - 29 Dec 2009
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 May 2009
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2007
Lannett Receives FDA Approval for Phentermine
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 12 Dec 2007
VIVUS Initiates Third Qnexa Phase 3 Trial in Obese Patients
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2007
VIVUS Initiates Second Qnexa Pivotal Phase 3 Trial in Obese Patients
Biopharmaceuticals
 HSMN NewsFeed - 22 Aug 2007
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 21 Jun 2007
VIVUS Completes End of Phase 2 Meeting with the FDA for Qnexa, a Treatment for Obesity
Biopharmaceuticals
 HSMN NewsFeed - 10 May 2006
VIVUS Announces Positive Phase 2 Clinical Trial Results With Qnexa, a Novel Therapy to Treat Obesity
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 2 additional stories matching:
Phentermine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.